Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction

Acta Neurol Scand. 2003 Aug;108(2):109-13. doi: 10.1034/j.1600-0404.2003.00126.x.

Abstract

Objectives: To test the hypothesis whether risk genotypes of the prothrombotic gene polymorphisms (I/D 4G5G PAI-1, G1691A factor V point mutation, factor VII Arg/Gln353) are risk factors for ACI in the Slovene population. The study sought an association between the insertion/deletion 4G/5G-plasminogen activator inhibitor 1 (PAI-1) gene polymorphism, the 1691G-A factor V point mutation or the arg353-to-gln factor VII gene polymorphism and atherothrombotic cerebral infarction (ACI).

Material and methods: Ninety-six Slovene patients who suffered ACI were compared with 115 control subjects clinically free of cerebrovascular disease. Insertion/deletion 4G/5G PAI-1 gene polymorphism, 1691G-A factor V point mutation and arg353-to-gln polymorphism in the factor VII were determined using polymerase chain reaction.

Results: The 4G4G genotype of 4G5G PAI-1 gene polymorphism was less frequent in cases (21.9%) than in controls (35.6%; OR = 0.5, 95% CI = 0.3-1; P = 0.033). No association was found either between the factor V point mutation (1691G-A) or the RR genotype of the factor VII Arg/Gln353 gene polymorphism and the risk of ACI using univariate analysis.

Conclusion: The 4G/4G-PAI-1 genotype might be a protective factor against ACI, whereas the factor V point mutation (1691G-A) and the factor VII Arg/Gln353 gene polymorphism have not proved to be risk factors for ACI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Case-Control Studies
  • Cerebral Infarction / genetics*
  • Factor V / genetics*
  • Factor VII / genetics*
  • Female
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Point Mutation*
  • Polymorphism, Genetic*
  • Risk Factors
  • Slovenia

Substances

  • Plasminogen Activator Inhibitor 1
  • Factor V
  • Factor VII